Dicot strengthens its management ahead of next phase in the company's development. Current VP and COO Elin Trampe is appointed CEO and will succeed current CEO Göran Beijer from April 1, 2022. Dicot will now strengthen and broaden the management team with the objective to take the company to the next phase and focus on clinical results, business development and international partnerships.

Current COO (Chief Operating Officer) and VP, Elin Trampe, will take over as CEO on April 1, 2022. Elin Trampe succeeds current CEO Göran Beijer, who has been CEO of Dicot for five years. Göran Beijer will continue to be actively involved in the company's development as a consultant and will work with the CEO primarily on business development and investor relations.

Elin Trampe was recruited in 2021 to Dicot as COO and VP. Elin Trampe has previously worked in the management team of Oasmia Pharmaceutical and Jacobs Douwe Egberts SE and held leading positions and international roles in several companies incl. the global companies Mondelez International and GE Global Operations.

Elin Trampe has extensive experience in business development, strategic international partnerships, operational excellence and product development.